Cellectis S.A. (CLLS) Financials

CLLS Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 289.2 million 229.3 million
Dec. 31, 2025 324.7 million 248.8 million
Sept. 30, 2025 343.0 million 242.6 million
June 30, 2025 354.0 million 256.9 million

CLLS Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -15.8 million ?
Dec. 31, 2025 -11.0 million 2.3 million
Sept. 30, 2025 -2.8 million 1.6 million
June 30, 2025 -10.6 million 1.3 million

CLLS Net Income

No data available :(

CLLS Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 185.7 million 67.5 million 25.9 million
Dec. 31, 2025 208.7 million 74.0 million 27.7 million
Sept. 30, 2025 190.2 million 49.7 million 37.6 million
June 30, 2025 196.2 million 49.6 million 39.7 million

CLLS Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 100.5 million
Dec. 31, 2025 100.3 million
Sept. 30, 2025 100.3 million
June 30, 2025 100.3 million

CLLS Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 265966 23.1 million 5.3 million -
Dec. 31, 2025 478569 24.4 million 1.5 million -
Sept. 30, 2025 1.2 million 24.1 million 2.5 million -
June 30, 2025 305000 23.1 million 2.3 million -

CLLS Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 5.8 million 4.6 million
Dec. 31, 2025 10.4 million 3.0 million
Sept. 30, 2025 35.2 million 2.4 million
June 30, 2025 16.7 million 2.4 million

CLLS

Price: $3.09

52 week price:
1.33
5.48

Earnings Per Share: -0.67 USD

Exchange: NGM

Sector: Healthcare

Industry: Biotechnology

Country: France

Volume: 1.9 million

Ebitda: -29.3 million

Market Capitalization: 307.3 million

Links: